Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

EU First to Clear AbbVie's Rinvoq for Alopecia Areata

Summary by Pharmaphorum
AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.

3 Articles

PharmaphorumPharmaphorum
Center

EU first to clear AbbVie's Rinvoq for alopecia areata

AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.

Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie’s Rinvoq wins EU approval for non-segmental vitiligo, the first systemic option.

·Ra'anana, Israel
Read Full Article
pressreach.compressreach.com

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - PressReach

Open the article to view the coverage from pressreach.com

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pressreach.com broke the news on Wednesday, July 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

AbbVie icon

AbbVie

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal